股票简称：广生堂 股票代码：300436 关于福建广生堂药业股份有限公司 申请向特定对象发行股票的 审核问询函的回复 保荐机构（主承销商） 中国（上海）自由贸易试验区浦明路 8 号 二〇二五年八月 关于福建广生堂药业股份有限公司申请向特定对象发行股票的审核问询函的回复 深圳证券交易所： 贵所于 2025 年 6 月 13 日签发的《关于福建广生堂药业股份有限公司申请向 特定对象发行股票的审核问询函》（审核函〔2025〕020025 号）（以下简称"问 询函"）已收悉。根据问询函的要求，福建广生堂药业股份有限公司（以下简称 "广生堂"、"公司"、"发行人"）会同保荐机构国联民生证券承销保荐有限 公司（以下简称"国联民生承销保荐"、"保荐机构"、"保荐人"）、国浩律 师（上海）事务所（以下简称"发行人律师"）、北京德皓国际会计师事务所（特 殊普通合伙）（以下简称"发行人会计师""会计师"）等相关方，本着勤勉尽 责、诚实守信的原则，就审核问询函所提问题逐项认真讨论、核查与落实，并逐 项进行了回复说明。现将相关问题回复如下，请予审核。 说明： 一、如无特别说明，本回复报告中使用的简称或名称释义具有与《福建广生 堂药业 ...

证券简称：广生堂 证券代码：300436 福建广生堂药业股份有限公司 Fujian Cosunter Pharmaceutical Co., Ltd. （福建省宁德市柘荣县富源工业园区 1-7 幢） 2025 年度向特定对象发行 A 股股票 募集说明书 （申报稿） 保荐人（主承销商） 中国（上海）自由贸易试验区浦明路 8 号 二〇二五年八月 福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票募集说明书 福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票募集说明书 重大事项提示 公司特别提示投资者对下列重大事项给予充分关注，并仔细阅读本募集说 明书中有关风险因素的章节。 一、本次向特定对象发行股票情况 发行人声明 本公司及全体董事、监事、高级管理人员承诺募集说明书及其他信息披露 资料不存在任何虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性及 完整性承担相应的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财 务会计资料真实、完整。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申 请文件及所披露信息的真实性、准确性、完整性作出保 ...

关于公司申请向特定对象发行股票的审核问询函回复（修订 稿）及募集说明书等申请文件更新的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：300436 证券简称：广生堂 公告编号：2025060 福建广生堂药业股份有限公司 福建广生堂药业股份有限公司（以下简称"公司"）于 2025 年 6 月 13 日收 到深圳证券交易所（以下简称"深交所"）出具的《关于福建广生堂药业股份有 限公司申请向特定对象发行股票的审核问询函》（审核函〔2025〕020025 号） （以下简称"问询函"），深交所发行上市审核机构对公司向特定对象发行股票 的申请文件进行了审核，并形成了审核问询问题。 特此公告。 福建广生堂药业股份有限公司董事会 2025 年 8 月 28 日 2 公司本次向特定对象发行股票事项尚需通过深交所审核，并获得中国证券监 督管理委员会（以下简称"中国证监会"）同意注册后方可实施，最终能否通过 深交所审核并获得中国证监会作出同意注册的决定及其时间尚存在不确定性。公 司将根据该事项进展情况及时履行信息披露义务，敬请广大投资者谨慎决策，注 意投资风险 ...

关于福建广生堂药业股份有限公司 申请向特定对象发行股票的审核问询函有 关财务事项的说明 德皓函字[2025]00000131 号 北 京 德 皓 国 际 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 关于福建广生堂药业股份有限公司 申请向特定对象发行股票的审核问询函 有关财务事项的说明 目 录 页 次 一、 关于福建广生堂药业股份有限公司申请向特定对 象发行股票的审核问询函有关财务事项的说明 1-142 关 于 福建广生堂药业股份有限公司 申请向特定对象发行股票的审核问询函 有关财务事项的说明 德皓函字[2025]00000131号 深圳证券交易所： 由福建广生堂药业股份有限公司转来的深圳证券交易所《关于福建广生堂药业股份有限 公司申请向特定对象发行股票的审核问询函》（审核函〔2025〕020025 号，以下简称问询 函）奉悉。我们已对问询函中由会计师核查并发表意见的部分进行了审慎核查，现汇报如下： 问询函问题 1： 根据申报 ...

国浩律师（上海）事务所 关 于 福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票 之 补充法律意见书（二） 上海市山西北路 99 号苏河湾中心 25-28 层 邮编：200085 25-28/F, Suhe Centre, No.99 North Shanxi Road, Shanghai 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5243 1670 网址/Website: http://www.grandall.com.cn 二〇二五年八月 | 第一节 | 声明事项 4 | | --- | --- | | 第二节 正 | 文 6 | | 第一部分 | 审核问询回复更新 6 | | 一、《审核问询函》之问题 | 1 6 | | 二、《审核问询函》之问题 | 2 70 | | 三、《审核问询函》之问题 | 3 99 | | 第三节 签署页 | 101 | 国浩律师（上海）事务所 补充法律意见书（二） 国浩律师（上海）事务所 关于福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票 之补充法律意见书（二） 致：福 ...

Market Overview - The Shanghai Composite Index fell by 1.76% on August 27, with only one industry, communication, showing an increase of 1.66%. The beauty care and real estate sectors experienced the largest declines, down 3.86% and 3.51% respectively. The pharmaceutical and biotechnology sector also saw a decrease of 2.73% [1]. Capital Flow Analysis - The main capital outflow from both markets totaled 129.75 billion yuan, with all sectors under the Shenwan classification experiencing net outflows. The computer industry led with a net outflow of 16.31 billion yuan, followed by the pharmaceutical and biotechnology sector with a net outflow of 12.33 billion yuan. Other sectors with significant outflows included electronics, automotive, and machinery equipment [1]. Pharmaceutical and Biotechnology Sector Performance - The pharmaceutical and biotechnology sector had 474 stocks, with 36 gaining and 438 losing value. Five stocks hit the daily limit up, while one stock hit the limit down. The sector saw a net outflow of 12.33 billion yuan, with 114 stocks experiencing net inflows, and 28 stocks seeing outflows exceeding 100 million yuan [2]. Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Jimin Health: +9.97% with a net inflow of 118.04 million yuan - Nanxin Pharmaceutical: +20.00% with a net inflow of 109.05 million yuan - BGI Genomics: +0.09% with a net inflow of 106.94 million yuan [2]. Major Outflows in Pharmaceutical Sector - The stocks with the largest net outflows included: - Hengrui Medicine: -3.45% with a net outflow of 901.64 million yuan - WuXi AppTec: -1.45% with a net outflow of 482.18 million yuan - Guangsheng Tang: -10.32% with a net outflow of 378.57 million yuan [3].

Group 1 - The gene sequencing sector experienced a decline of 3.38%, ranking among the top losers in the concept sector as of the market close on August 27 [2][3] - Within the gene sequencing sector, major companies such as Guangshentang, Ruian Gene, and Puni Testing saw significant declines, while a few companies like Dean Diagnostics, Aiko Optoelectronics, and Kingmed Diagnostics recorded gains of 5.81%, 3.67%, and 2.11% respectively [2][3] - The gene sequencing sector faced a net outflow of 1.543 billion yuan from main funds, with 53 stocks experiencing net outflows, and five stocks seeing outflows exceeding 100 million yuan [3][4] Group 2 - Guangshentang led the outflow with a net withdrawal of 379 million yuan, followed by Anke Bio, Huace Testing, and Yuheng Pharmaceutical with net outflows of 189 million yuan, 118 million yuan, and 116 million yuan respectively [3][4] - On the other hand, the stocks with the highest net inflows included BGI Genomics, Kingmed Diagnostics, and Jiuzhoutong, attracting net inflows of 107 million yuan, 106 million yuan, and 79 million yuan respectively [3][5] - The overall market sentiment in the gene sequencing sector appears to be bearish, as indicated by the significant net outflows and the performance of major stocks within the sector [2][3]

Market Overview - The A-share market experienced a decline in the afternoon, with the Shanghai Composite Index falling by 1.76%, the Shenzhen Component Index down by 1.43%, and the ChiNext Index decreasing by 0.69% [1] - The total trading volume exceeded 3.19 trillion yuan, marking the third instance in A-share history to surpass 3 trillion yuan in a single day [1] Sector Performance - Rare earth permanent magnet stocks showed strong performance, with Beikong Technology hitting the daily limit and Northern Rare Earth rising over 8%, briefly reaching the top of the Tonghuashun hot stock list [4][7] - The computing power leasing sector also saw gains, with Hongjing Technology surging over 19% at one point, closing up 8.71% [4] - In contrast, sectors such as real estate, liquor, beauty care, and innovative pharmaceuticals faced significant declines [4] Notable Stocks - Cambrian-U saw a rise of over 10% during the day, briefly surpassing Kweichow Moutai in stock price, and closing up 3.24% at 1372.1 yuan per share [4] - Kweichow Moutai closed down 2.27% at 1448 yuan per share [4] - Cambrian has increased over 93% since August [4] Rare Earth Sector Drivers - Key factors driving the rare earth sector include: - Policy support from the Ministry of Industry and Information Technology, which recently issued guidelines for rare earth mining and separation [10] - Significant revenue growth reported by Northern Rare Earth, with a 45.24% increase in revenue to 18.866 billion yuan and a staggering 1951.52% increase in net profit to 931 million yuan [10] - Rising prices of rare earth minerals and magnetic materials, contributing to a tight supply-demand balance [10] - Positive outlook for the entire rare earth permanent magnet industry chain, with strong orders from both upstream and downstream players [10] - Technological advancements by leading companies, enhancing competitiveness while reducing costs [10] Innovative Pharmaceuticals Sector - The innovative pharmaceuticals sector faced a downturn, with stocks like Yuekang Pharmaceutical dropping over 16%, and others like Hotgen Biotech and Guangsheng Tang falling more than 10% [11] - Analysts suggest that as the interim report season concludes, market focus will shift towards new directions, with continued optimism for innovative pharmaceuticals and overseas expansion [12]

Market Overview - The chemical pharmaceutical sector experienced a decline of 3.21% on August 27, with Yuyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Stock Performance - Notable gainers included: - Nanjing New Pharmaceutical (688189) with a closing price of 16.98, up 20.00% [1] - Ailisi (688578) with a closing price of 111.31, up 17.00% [1] - Maiwei Biotech (688062) with a closing price of 45.08, up 6.07% [1] - Significant losers included: - Yuyuan Pharmaceutical (688658) with a closing price of 26.45, down 16.82% [2] - Guangshengtang (300436) with a closing price of 124.55, down 10.32% [2] - Lifang Pharmaceutical (003020) with a closing price of 32.31, down 10.00% [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 6.417 billion yuan from institutional investors, while retail investors contributed a net inflow of 5.263 billion yuan [2][3] - The table of capital flow indicates that major stocks like Nanjing New Pharmaceutical had a net inflow of 114 million yuan from institutional investors [3]

Market Overview - The A-share market experienced a pullback in the afternoon, with the Shanghai Composite Index down 1.76%, the Shenzhen Component down 1.43%, and the ChiNext Index down 0.69% [1] - The total trading volume exceeded 3.19 trillion yuan, marking the third instance in A-share history to surpass 3 trillion yuan in a single day [1] Active Sectors - Rare earth permanent magnet stocks showed strong performance, with Beikong Technology hitting the daily limit and Northern Rare Earth rising over 8%, leading the hot stock list [3][4] - The computing power leasing concept also gained traction, with Hongjing Technology surging over 19% at one point, closing up 8.71% [3] Rare Earth Sector Drivers - Key drivers for the rare earth sector include: 1. Policy support from the Ministry of Industry and Information Technology, which recently issued regulations on rare earth mining and separation [3] 2. Significant revenue growth reported by Northern Rare Earth, with a 45.24% increase in revenue to 18.866 billion yuan and a staggering 1951.52% increase in net profit to 931 million yuan [3][4] 3. Continuous price increases for rare earth minerals and magnetic materials, maintaining a tight supply-demand balance [4] 4. Positive industry fundamentals, with robust demand from both upstream and downstream sectors [4] 5. Technological advancements by leading companies, enhancing competitiveness and reducing costs [4] Innovation Drug Sector - The innovation drug sector faced a downturn, with notable declines in stocks such as Yuekang Pharmaceutical down over 16% and Hejing Bio down over 10% [5] - Analysts suggest that as the mid-year report season concludes, market focus will shift towards new directions, particularly in innovation drugs and overseas expansion [6]